China

The rollout follows the drug’s approval in China in June 2026 and marks the start of its wider clinical use for people requiring urgent post-exposure protection against rabies.

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by recurring symptoms, with the CIC report indicating that China had more than 54 million people living with AD in 2024.

The share repurchase programme will be funded primarily through proceeds from the sale of an approximately 6% stake in Gland Pharma for about US$294 million.

The company recorded non-IFRS net profit of RMB 97.23 million (US$13.7 million), while its IFRS net loss narrowed 98% year-on-year. Everest ended the period with RMB 1.859 billion (US$261.8 million) in cash.

If approved and launched, the vaccine will complement CanSinoBIO’s recently approved three-component DTaP vaccine, Tripecia® (DT3cP Infant), expanding the company’s pertussis-containing vaccine portfolio across age groups.

The latest approval expands the clinical use of ivonescimab in China and follows previous NMPA authorisations for regimens containing the molecule.

Vanflyta received approval in China in June 2026 for use in adults with newly diagnosed FLT3-ITD-positive AML, as determined by an appropriate validated diagnostic test.

The new venture will initially manufacture biologic drug substances that the two companies mutually select for global markets.

AsymBio plans to use the additional capital to expand its research and development capabilities, GMP manufacturing lines and high-containment facilities.